Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Esperion Therapeutics Inc a un objectif de cours consensuel de $6.05 basé sur les évaluations de 11 analystes. Le plus élevé est $16, publié par HC Wainwright & Co. le septembre 19, 2025. Le plus bas est $2.5, publié par B of A Securities le juin 20, 2024. Les 3 évaluations d’analystes les plus récentes ont été publiées par Piper Sandler, HC Wainwright & Co. et HC Wainwright & Co. le novembre 25, 2025, septembre 19, 2025 et juin 17, 2025, respectivement. Avec un objectif de cours moyen de $13.67 entre Piper Sandler, HC Wainwright & Co. et HC Wainwright & Co., il existe une variation implicite de 284.44% upside pour Esperion Therapeutics Inc selon ces dernières évaluations d’analystes.
1calculé à partir des notes des analystes
| Buy Now | Get Alert | ||||||
|---|---|---|---|---|---|---|---|
| 11/25/2025 | Buy Now | 153.16% | Piper Sandler | → $9 | Initiates | → Overweight | Get Alert |
| 09/19/2025 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2025 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2025 | Buy Now | 12.52% | Needham | $5 → $4 | Maintains | Buy | Get Alert |
| 04/25/2025 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2025 | Buy Now | 40.65% | Needham | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2025 | Buy Now | -15.61% | Goldman Sachs | $4 → $3 | Maintains | Neutral | Get Alert |
| 04/08/2025 | Buy Now | 40.65% | Needham | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2025 | Buy Now | 12.52% | Citizens Capital Markets | $4 → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/04/2025 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 12.52% | JMP Securities | $7 → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/11/2025 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2025 | Buy Now | 96.91% | JMP Securities | $7 → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/23/2025 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | — | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 12.52% | Goldman Sachs | → $4 | Reinstates | → Neutral | Get Alert |
| 12/17/2024 | Buy Now | 125.04% | Cantor Fitzgerald | → $8 | Initiates | → Overweight | Get Alert |
| 12/13/2024 | Buy Now | 68.78% | Needham | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 68.78% | Needham | $8 → $6 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 125.04% | Needham | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | -29.68% | B of A Securities | $2.9 → $2.5 | Downgrade | Neutral → Underperform | Get Alert |
| 05/22/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/21/2024 | Buy Now | 350.07% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 125.04% | Needham | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 125.04% | Needham | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 125.04% | Needham | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 350.07% | HC Wainwright & Co. | $22 → $16 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 125.04% | Needham | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | -29.68% | B of A Securities | $4 → $2.5 | Downgrade | Buy → Neutral | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | — | Reinstates | → Neutral | Get Alert |
| 11/13/2023 | Buy Now | 518.85% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 125.04% | Needham | $9 → $8 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 153.16% | Needham | → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 518.85% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 153.16% | Needham | $10 → $9 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 518.85% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 12.52% | B of A Securities | $1.25 → $4 | Upgrade | Underperform → Buy | Get Alert |
| 06/01/2023 | Buy Now | 518.85% | HC Wainwright & Co. | → $22 | Reiterates | → Buy | Get Alert |
| 05/09/2023 | Buy Now | 181.29% | Needham | $12 → $10 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | 237.55% | Needham | → $12 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 237.55% | Needham | → $12 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | -15.61% | Morgan Stanley | $9 → $3 | Maintains | Equal-Weight | Get Alert |
| 03/16/2023 | Buy Now | -57.81% | B of A Securities | $8 → $1.5 | Downgrade | Neutral → Underperform | Get Alert |
| 03/16/2023 | Buy Now | 237.55% | Needham | $16 → $12 | Maintains | Buy | Get Alert |
| 03/16/2023 | Buy Now | 518.85% | HC Wainwright & Co. | → $22 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 96.91% | Credit Suisse | $6.5 → $7 | Upgrade | Underperform → Neutral | Get Alert |
| 03/06/2023 | Buy Now | 321.94% | JMP Securities | → $15 | Reiterates | → Market Outperform | Get Alert |
| 03/06/2023 | Buy Now | 350.07% | Needham | $12 → $16 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 518.85% | HC Wainwright & Co. | → $22 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 153.16% | JP Morgan | $8 → $9 | Maintains | Neutral | Get Alert |
| 02/27/2023 | Buy Now | 125.04% | B of A Securities | → $8 | Reinstates | → Neutral | Get Alert |
| 02/22/2023 | Buy Now | 237.55% | Needham | → $12 | Reiterates | → Buy | Get Alert |
Le dernier objectif de prix pour Esperion Therapeutics (NASDAQ:ESPR) a été rapporté par Piper Sandler le novembre 25, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $9.00 s'attendant à ce que ESPR se rise dans les 12 prochains mois (un possible changement de 153.16% upside). 11 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
La dernière note d'analyste pour Esperion Therapeutics (NASDAQ:ESPR) a été fournie par Piper Sandler, et Esperion Therapeutics initié leur note overweight.
La dernière amélioration pour Esperion Therapeutics Inc a eu lieu le juin 15, 2023 lorsque B of A Securities a augmenté leur objectif de prix à $4. B of A Securities avait précédemment an underperform pour Esperion Therapeutics Inc.
La dernière réduction pour Esperion Therapeutics Inc a eu lieu le juin 20, 2024 lorsque B of A Securities a changé leur objectif de prix de $2.9 à $2.5 pour Esperion Therapeutics Inc.
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Esperion Therapeutics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Esperion Therapeutics a été déposée le novembre 25, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 25, 2026.
Bien que les évaluations soient subjectives et changeront, la dernière note de Esperion Therapeutics (ESPR) était un initié avec un objectif de prix de $0.00 à $9.00. Le prix actuel de Esperion Therapeutics (ESPR) est de $3.56, ce qui est within la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.
Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise
Données de marché fournies par API Benzinga